KPTI vs LRCX · rev $68.5M vs P/E 71, rev $23.23B
Karyopharm Therapeutics Inc (KPTI) versus Lam Research Corp (LRCX) — a side-by-side from cached financials, not a winner call.
Karyopharm Therapeutics Inc (KPTI) is a biotechnology company listed on US.
Lam Research Corp (LRCX) is a semiconductor equipment & materials company listed on NASDAQ. It is led by Timothy M. Archer.
Latest reported KPTI revenue for 2026-06-30 was $68.5M. Net income was -$89.4M. Revenue was up 95.3% from 2026-03-31 to 2026-06-30. KPTI currently screens at market cap $205.6M.
Latest reported LRCX revenue for 2026-06-28 was $23.23B. Net income was $7.27B. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
KPTI currently screens at market cap $205.6M. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
Not investment advice. Open the KPTI and LRCX stock pages for the full models.
Not investment advice.